In recurrent prostate cancer, PSMA PET/CT changes management in two-thirds of cases

New research confirms the high impact of PSMA PET/CT in the detection and management of recurrent disease in prostate cancer patients. In initial results from a multicenter trial assessing the impact of 18F-DCFPyL prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT), a PET-directed change in management was observed in two-thirds of patients. The research was presented at the Society of Nuclear Medicine and Molecular Imaging’s 2020 Virtual Annual Meeting.